Results of a Phase I-II Study of Fenretinide and Rituximab for Patients with B-Cell Lymphomas

被引：0
|
作者：
Cowan, Andrew J. [1 ]
Stevenson, Philip [2 ]
Gooley, Ted A. [2 ]
Frayo, Shani L. [2 ]
Oliveira, George R. [3 ]
Smith, Stephen D. [1 ,4 ]
Green, Damian J. [1 ,2 ]
Roden, Jennifer E. [5 ]
Pagel, John M. [6 ]
Wood, Brent L. [4 ,7 ]
Press, Oliver W. [1 ,4 ]
Gopal, Ajay K. [1 ,8 ]
机构：
[1] Univ Washington, Dept Med, Div Med Oncol, Seattle, WA USA
[2] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[3] Harvard Univ, Sch Med, Dept Radiol, MGH Hosp, Boston, MA 02115 USA
[4] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA
[5] Univ Washington, Dept Med, Seattle, WA USA
[6] Swedish Med Ctr, Seattle, WA USA
[7] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA
[8] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Multicentre phase II study of CyclOBEAP plus rituximab in patients with diffuse large B-cell lymphoma
    Niitsu, Nozomi
    Kohri, Mika
    Hagiwara, Yuki
    Tanae, Ken
    Takahashi, Naoki
    Bessho, Masami
    Okamoto, Masataka
    HEMATOLOGICAL ONCOLOGY, 2010, 28 (02) : 68 - 74
  • [22] RETREATMENT WITH RITUXIMAB IN 178 PATIENTS WITH RELAPSED AND REFRACTORY B-CELL LYMPHOMAS: A SINGLE INSTITUTION STUDY
    Johnston, M.
    Bouafia-Sauvy, F.
    Broussais-Guillaumont, F.
    Michallet, A. -S.
    Traulle, C.
    Salles, G.
    Coiffier, B.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 391 - 391
  • [23] Preliminary Results from a Phase I Study of SHC014748M in Patients with Relapsed or Refractory Indolent B-Cell Lymphomas
    Xu, Wei
    Jin, Jie
    Zhou, Keshu
    Wang, Li
    Zhu, Huayuan
    Qian, Jiejing
    Huang, Jianying
    Zhou, Fuling
    Xu, Xiaohong
    Wang, Zhiqiang
    Guo, Wei
    Li, Jianyong
    BLOOD, 2019, 134
  • [24] Rituximab for the treatment of diffuse large B-cell lymphomas
    Held, Gerhard
    Poschel, Viola
    Pfreundschuh, Michael
    EXPERT REVIEW OF ANTICANCER THERAPY, 2006, 6 (08) : 1175 - 1186
  • [25] Rituximab in the treatment of diffuse large B-Cell lymphomas
    Coiffier, B
    SEMINARS IN ONCOLOGY, 2002, 29 (01) : 30 - 35
  • [26] Clinical impact of rituximab in managing B-cell lymphomas
    Grillo-López, AJ
    McLaughlin, P
    Wey, K
    Dallaire, BK
    Nasazideh, H
    Eldredge, E
    Leonerd, JE
    White, CA
    Cabanillas, F
    ONCOLOGY-NEW YORK, 2001, 15 (03): : 11 - +
  • [27] A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer
    Colombo, Nicoletta
    Formelli, Franca
    Cantu, Maria Grazia
    Parma, Gabriella
    Gasco, Milena
    Argusti, Alessandra
    Santinelli, Alfredo
    Montironi, Rodolfo
    Cavadini, Elena
    Baglietto, Laura
    Guerrieri-Gonzaga, Aliana
    Viale, Giuseppe
    Decensi, Andrea
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2006, 15 (10) : 1914 - 1919
  • [28] Japanese multicenter phase II study of CHOP followed by radiotherapy in stage I-II, diffuse large B-cell lymphoma of the stomach
    Ishikura, S
    Tobinai, K
    Ohtsu, A
    Nakamura, S
    Yoshino, T
    Oda, I
    Takagi, T
    Mera, K
    Kagami, Y
    Itoh, K
    Tamaki, Y
    Suzumiya, J
    Taniwaki, M
    Yamamoto, S
    CANCER SCIENCE, 2005, 96 (06): : 349 - 352
  • [29] RADIOIMMUNOTHERAPY (RIT) WITH 177LUTETIUM-DOTA-RITUXIMAB (177LU-D-R): FINAL RESULTS OF A PHASE I/II - STUDY IN 31 PATIENTS WITH RELAPSING FOLLICULAR, MANTLE CELL AND OTHER INDOLENT B-CELL LYMPHOMAS
    Lohri, A.
    Forrer, F.
    Oechslin-Oberholzer, C.
    Herrmann, R.
    Maecke, H.
    Mueller-Brand, J.
    ANNALS OF ONCOLOGY, 2011, 22 : 188 - 188
  • [30] Value of surveillance studies for patients (pts) with stage I-II diffuse large B-cell lymphoma (DLBCL) in the rituximab (R) era.
    Hiniker, Susan M.
    Pollom, Erqi L.
    Khodadoust, Michael S.
    Kozak, Margaret M.
    Advani, Ranjana H.
    Hoppe, Richard T.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345